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Dendritic cells (DCs) are the antigen presenting cells that initiate and regulate immunity. By studying these
cells in vivo, we will be able to move beyond standard approaches and design vaccines that directly harness
the elaborate properties of DCs to control immunity.
‘‘The challenge for us as immunologists is to understand how the
various elements work and fit together, and then to develop innovative solutions that do better than
nature.. Immunity ranks with the
most complex of complex systems,
along with neurobiology and climate change.’’ P.C. Doherty and
S.J. Turner, Immunity 27: 363–365
The traditional vaccines that we know
induce immunity against specific microbial antigens and prevent infectious diseases. These vaccines are a major success story and emanate in large part
from the discoveries of Louis Pasteur.
His first vaccine against chicken cholera
was created in 1879, and his most famous
vaccine against human rabies was created in 1885 (Dubos, 1988). Pasteur’s
research was based on the science of
microbiology, i.e., his discovery that distinct microbes are the causes of disease
and that an attenuated microbe can induce long-lived protection against infection by the nonattenuated form of that organism. These breakthroughs occurred
before there was any clear understanding
of vaccine immunity, which began with
the discovery of antibodies by von Behring and Kitasato in the 1890s. After the
great advances in immunology during
the twentieth century, a new vaccine era
has finally arrived on the basis of key immune principles.
Vaccines can be defined as formulations that induce specific, nontoxic, and
long-lasting immune responses to prevent or treat disease. The new vaccines
that immunological research can now develop will deliver the relevant antigens and
adjuvants (substances that work with an-

tigens to either enhance or silence immunity) to redirect the immune system for
the individual’s benefit (Pulendran and
Ahmed, 2006) (Figure 1). The dendritic
cell (DC) biology that is described in this
issue of Immunity provides a foundation
on which to create vaccines that not only
induce protection against microbes but
also deal with cancer (see Melief, 2008),
autoimmunity, and allergy (see Belkaid
and Oldenhove, 2008).
Here, I will discuss four features of DCs
that establish their central role in developing new vaccine strategies: location, antigen handling, maturation, and subsets. As
Doherty and Turner write in the introductory quotation, vaccine biology compels
us to pull these features of DCs together
and ‘‘develop innovative solutions that
do better than nature.’’
Location of Dendritic Cells
In the past, emphasis has been placed on
the capacity of DCs to pick up antigens in
the periphery, including vaccines at an injection site, and then migrate from peripheral tissues to the T cell areas of lymphoid
organs to initiate immunity. The underlying biology is elegant (see Alvarez et al.,
2008, this issue), yet more information is
needed on the types of DCs that pick up
vaccine antigens at an injection site,
such as skin or muscle, and initiate immunity. Now additional origins of DCs are apparent (Shortman and Naik, 2007) (see
López-Bravo and Ardavı́n, 2008, this issue). In the steady state, most DCs in lymphoid organs actually arise from a blood
precursor (Fogg et al., 2006; Liu et al.,
2007). These precursors can proliferate
in the lymphoid organ, a process driven
by flt-3 ligand (Waskow et al., 2008). Another potentially major source of DCs is

monocytes. Monocyte-derived DCs accumulate in lymphoid tissues during
some infections, e.g., Leishmania major
(Leon et al., 2007). Learning how to mobilize and access these other reservoirs of
DCs in vivo could enhance the quality
and efficacy of vaccine-induced immunity.
Effective mucosal immunity or resistance at body surfaces is a major hurdle
for vaccine development, probably because mucosal surfaces are specialized
to sustain nonreactivity to all the innocuous antigens within commensal microorganisms and the proteins in the air we
breathe and the foods we eat. HIV-1 vaccines for example will probably need to
induce mucosal immunity because this
virus is most often transmitted via a
mucosal route and quickly leads to a
rapid loss of T cells in the intestine
(Brenchley et al., 2004; Mehandru et al.,
2004). DCs are uniquely located beneath
the epithelium at several mucosal surfaces, such as the airway, intestine, and
stomach. Intravital microscopy has
helped reveal that these cells insinuate
their dendritic processes between epithelial cells to enter the mucosal lumen
(Chieppa et al., 2006; Niess et al., 2005).
A critical goal is to determine whether
vaccines can be designed to access
these mucosal DCs to bring about better
mucosal immunity. Depending upon the
medical condition under investigation,
desirable mucosal vaccines need to induce both antibodies and T cells that
block infection at the site of pathogen entry, or alternatively activate suppressor
T cells (‘‘regulatory T cells’’), which have
the potential to block the inflammatory
and allergic diseases at mucosal surfaces
(see Belkaid, 2008). One gap in current
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knowledge relates to antigen
tigen synthesis in an infected
and adjuvant delivery to DCs
cell; e.g., attenuated viral
associated with organized
vectors can elicit CD8+ cytotoxic T cells, but they also
mucosal lymphoid tissues
elicit antivector immunity
such as Peyer’s patches. Bethat can compromise the efficause the latter are covered
cacy of booster doses of
by a distinctive epithelium
vaccine. Crosspresentation
rich in antigen-transporting
could overcome these hurM cells, receptors on these
dles because it provides
M cells, if ligated, could ima route for ‘‘exogenous’’ vacprove vaccine delivery to the
cine proteins to be processed
DCs that lie underneath (Noand to gain access to MHC I.
chi et al., 2007).
Mechanisms are under study
A hallmark of DC location is
(Kasturi
and
Pulendran,
their abundance in lymphoid
2008); the latest concept is
tissues, particularly the T cell
that there are special endoareas (Alvarez et al., 2008).
somal compartments where
Numerically, DCs represent
Figure 1. Some Key Challenges for Vaccines in Immunological
internalized antigens are
a tiny fraction of total cells,
Science and Medicine
crosspresented
(Burgdorf
but their processes conet al., 2008; Di Pucchio
stantly probe the environment, forming a vast and labyrinthine net- sets (see below) in vivo (Hawiger et al., et al., 2008). Certain receptors may be
work through which lymphocytes must 2001). Retroviral vectors gain improved specialized to traverse the crosspresenpass (Lindquist et al., 2004). This sets immunogenicity if the envelope is engi- tation pathway, such as Fc receptors for
the stage for the selection of rare but spe- neered to target the DC-SIGN (CD209) antibody complexes (Dhodapkar et al.,
cific clones of lymphocytes during the ini- receptor on DCs (Yang et al., 2008). The 2002a; Regnault et al., 1999), receptors
tial steps of vaccination. It is now feasible efficacy of HIV DNA vaccines can be im- for dying cells (den Haan et al., 2000; Dhoto target vaccine antigens directly to proved by targeting to DEC-205 (Nchinda dapkar et al., 2002b; Iyoda et al., 2002),
these numerous DCs in the T cell areas et al., 2008). Low doses of protein-based and certain C-type lectin receptors such
and modulate their function with adju- vaccines have also been targeted to as DEC-205 (Bonifaz et al., 2004; Bozvants (Bonifaz et al., 2004; Boscardin DEC-205 along with poly IC as adjuvant. zacco et al., 2007). Targeting these recepet al., 2006; Trumpfheller et al., 2008; This leads to a large T helper 1 (Th1) cell tors with vaccines may help to overcome
Trumpfheller et al., 2006).
type of T cell response, whereas targeting the crosspresentation hurdle during vacto the DCIR2 receptor on another subset cination. Nonetheless, I urge the field to
of DCs allows both IFN-g and IL-4 to be move beyond the dominant use of ovalbuAntigen Handling by Dendritic Cells
Because of the molecular identification of induced (Soares et al., 2007; Trumpfheller min in C57Bl/6 mice as the model antigen
the DEC-205 (CD205) antigen uptake re- et al., 2008). Receptor targeting not only for these studies because it is orders of
ceptor on DCs (Jiang et al., 1995), it has enhances antigen uptake and processing magnitude more sensitive than the antibecome apparent that these cells express a hundred fold but also facilitates re- gens that need to be crosspresented to
a plethora of such receptors, often lectins. search on DCs and receptor function create effective vaccines. Ovalbumin
These molecules deliver antigens to pro- in vivo without the need to isolate the may be distorting the standards for discessing compartments, leading to the cells (Hawiger et al., 2001)(Bonifaz et al., covering safe, defined, protein-based
vaccines.
presentation of antigen fragments on 2004).
MHC and CD1 molecules (see VilladanAnother major hurdle for vaccine design
gos and Young, 2008). Endocytic recep- is ‘‘crosspresentation.’’ Nonreplicating Maturation of Dendritic Cells
tors in some cases also signal DC activa- vaccines, e.g., the Salk inactivated viral The most intricate feature of DCs is their
tion or deactivation (Robinson et al., vaccine, as well as protein vaccines, capacity to differentiate or mature along
2006). Although DCs are able to capture e.g., the diphtheria-pertussis-tetanus many different lines. This is driven by
antigens as solutes in endocytic vacuoles (DPT) vaccine, are capable of inducing many different types of stimuli including
(‘‘pinocytosis’’), the identification of up- antibody and CD4+ T cell immunity, suffi- (1) microbial ligands for pattern recognitake receptors changes the study of DC cient in quantity and quality to provide tion receptors, (2) innate lymphocytes,
biology in vivo and opens new possibili- protection against the polio virus and (3) immune complexes acting on Fc reties for efficient vaccine delivery to DCs DPT toxins, respectively. However, in or- ceptors, and (4) additional environmental
der for protein-based vaccines to elicit re- and endogenous stimuli termed ‘‘alarand vaccine design.
By identifying specific ligands for anti- sistance to HIV and cancer, a nonreplicat- mins.’’ Maturing DCs, depending on the
gen uptake receptors on DCs, or by using ing form of an antigen needs to elicit stimulus as well as environmental factors
monoclonal anti-receptor antibodies as MHC-class-I-restricted, CD8+ or cyto- affecting lymphocytes, then determine
surrogate ligands, one can efficiently tar- toxic T cells. Typically, MHC I presenta- the type of response, which can be either
get vaccine antigens to DCs or their sub- tion requires microbial replication and an- immunogenic, providing resistance, or
320 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.
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tolerogenic, silencing an immune response. One sphere of immunity that is
particularly sensitive to the type of stimulus encountered by DCs is CD4+ helper
T cell differentiation. The specific pathway
followed by CD4+ T cells, whether it involves Th1, Th2, Th17, Tf, Tr1, or Treg
cell differentiation, is significantly governed by DCs.
A major challenge is to understand how
vaccine adjuvants influence DC maturation in vivo, so that the resulting immunity
will appropriately resist a particular pathogen or disease. Two important areas of
science are pattern recognition receptors
and DC subsets (next) (Agrawal et al.,
2003; Shah et al., 2003). Synthetic double-stranded RNA, poly IC, is recognized
by TLR3 and MDA-5 receptors, and it
can polarize CD4+ T cells along a Th1
cell pathway when delivered with antigens
to the CD205+ DC subset (Soares et al.,
2007; Trumpfheller et al., 2008). TLR7TLR8 and TLR9 ligands also can serve
as adjuvants for responses by IFN-g-producing T cells (Wille-Reece et al., 2006). In
contrast, ligands for the dectin receptor,
when applied to bone-marrow-derived
DCs, lead to IL-2 and IL-10 production
and seem to favor Th17 cell differentiation
(LeibundGut-Landmann et al., 2007). Ligation of c-kit and TSLP receptors allows
DCs to induce Th2 cell responses, a process that takes place in the presence of
certain allergens such as the house
dust-mite
allergen
(Krishnamoorthy
et al., 2008; Soumelis et al., 2002). These
observations set the stage to design vaccines that direct the antigen-presenting
DCs and/or the responding T cells to develop selected types of immunity; e.g.,
Th1 T cells help resist many viruses and
tumors, Th2 cells mediate parasitic infections, and Th17 cells respond to certain
extracellular bacteria and fungi.
An exciting new area will be to design
vaccines to specifically silence unwanted
immune reactions by taking advantage of
DC programs that lead to tolerance. DCs
can induce tolerance by deleting or silencing T cells (Brimnes et al., 2003; Hawiger et al., 2004), but they can also induce differentiation of suppressive T cells,
e.g., IL-10 producers (Levings et al., 2005;
Macdonald et al., 2005), and foxp3+ Treg
cells (Kretschmer et al., 2005; Luo et al.,
2007). Environmental cytokines such as
IL-10 and TGF-b, as well as vitamin A,
can be critical. The CD8+ or CD205+ sub-

set of DCs in mice produces more TGFb (Wang et al., 2008; our unpublished
data) and also metabolizes vitamin A to
retinoic acid; TGF-b and retinoic acid are
cofactors for Treg cell development
(Coombes et al., 2007; Sun et al., 2007).
A different pathway involves the E-cadherin that DCs use to bind other cells or
other DCs; when the DCs detach, the
E-cadherin signals upregulation of the
lymph-node-homing receptor CCR7 and
production of tolerizing amounts of IL-10
(Jiang et al., 2007). In yet another route
(and there will be many others!), ligation
of select ILT molecules on DCs makes
them tolerogenic (Liang et al., 2008; Manavalan et al., 2003). For these reasons, we
can start to think about designing vaccines that harness antigen-presenting
DCs to regulate and suppress specific,
undesirable immune responses in allergy,
autoimmunity, and transplantation.
Subsets of Dendritic Cells
Certain markers divide DCs into distinct
forms termed subsets (Villadangos and
Young, 2008). Many of these markers
are receptors involved in pattern recognition and antigen presentation, the key
steps in innate and adaptive immunity.
All subsets, however, can share characteristic features of the DC lineage such
as an unusual, probing dendritic morphology, high amounts of MHC class II, and
potent T cell-stimulating activity.
DC subsets are likely to be selected to
recognize distinct pathogens or forms of
antigen and then follow through with distinct innate and adaptive responses (Liu,
2005; Shortman and Naik, 2007). To illustrate, plasmacytoid DCs express Toll-like
receptors (TLR7, TLR8, and TLR9) and respond to viral and self-nucleic acids with
vigorous type I interferon production (Kadowaki et al., 2000) (Boonstra et al., 2003)
(Boule et al., 2004) (Lande et al., 2007); the
plasmacytoid subset also has special endosomal compartments for crosspresentation on MHC I (Di Pucchio et al., 2008).
Another subset of CD205+ ‘‘myeloid’’
DCs seems specialized to take up and
crosspresent antigens from dying cells
(den Haan et al., 2000; Iyoda et al.,
2002). Within the skin, there are DC subsets that are specialized to induce either
cytotoxic T cells or antibody-forming B
cells (Klechevsky et al., 2008, this issue).
In all these instances, it is likely that the
immunogenic DC subset, and conceiv-

ably a tolerogenic DC subset as well,
must present the relevant vaccine antigen
and directly respond to the vaccine adjuvant (Sporri and Reis e Sousa, 2005;
Sporri and Reis e Sousa, 2003). DC subsets therefore greatly expand the number
of targets that vaccines can exploit to
control immunity.
Monocyte-derived DCs comprise another type of DC subset(s). The term is
used in two contexts and their relationship
is still not established. In vivo, monocytederived DCs were recently described in
lymph nodes during infection of mice
with the parasite L. major (Leon et al.,
2007; see López-Bravo and Ardavı́n,
2008), but their functional properties relative to other DC subsets in lymphoid tissues remain undefined. In addition, for
many years scientists have been stimulating monocytes in vitro to develop many
features of DCs (Romani et al., 1994; Sallusto and Lanzavecchia, 1994). Human
monocyte-derived DCs are notably plastic depending upon the type of cytokines
in the culture, e.g., IL-4, IL-15, or type I interferon (Dubsky et al., 2007). It still needs
to be determined whether a vaccine approach based on monocyte-derived DCs
can influence the immune outcome.
DC subsets can vary from one another
in all the other features described above:
location, receptors, and maturation programs. Nonetheless, given the potential
importance of DC-subset diversity in determining the outcome of immunization,
particularly the need to generate CD8+ cytotoxic T cell immunity in cancer and infections like AIDS, it is unsettling that the
information base for DC subsets, including pattern-recognition receptors, is scant
for DCs in intact human lymphoid and
mucosal tissues.
An Exciting but Challenging Time
for Vaccine Science
It is widely acknowledged that fundamental discoveries are needed to develop new
vaccines (Klausner et al., 2003). Vaccine
science will identify and understand the
antigens, adjuvants, and protective cells
that provide specific, durable, and nontoxic therapies. In the case of AIDS vaccines, discovery-dedicated academic
scientists are finally beginning to receive
the support and coordination they require,
particularly through the new initiatives of
the Bill and Melinda Gates Foundation
and the National Institute of Allergy and
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Infectious Diseases. Unfortunately, the
same cannot be said for other disease
targets, particularly cancer. Immunologic
approaches to cancer have proven to be
effective especially with monoclonal antibodies. However, cellular- and vaccinebased therapies remain underappreciated
and poorly supported areas of research,
either as stand-alone approaches or in
combination with other therapies (see Melief, 2008). Cancer patients also illustrate
most poignantly the difficulties with the
currently prevailing therapies against diseases that interact with the immune system. These drugs can have toxic and ‘‘offtarget’’ side effects and typically require
frequent use. Vaccines, in contrast, offer
the ultimate ‘‘targeted’’ therapy because
they have the capacity to reach many specific targets in tandem, such as the many
alterations in cancer cells, and because
they remain directed and durable in their
effects.
Vaccine design is often considered an
empirical activity. But let us not be derailed by the ‘‘empirical’’ or ‘‘descriptive’’
label. The fundamental challenges are scientific, in that we must discover diseaserelevant antigens, adjuvants, and protective mechanisms. Immunology is ready
to address these challenges to understand how the various elements work
and fit together. This is because the immune system deals directly with the myriad of disease targets, not only hundreds
of different infections but also many cancers as well as autoimmune, inflammatory, and allergic conditions.
Yet there are at least three ways in
which vaccine science differs from the
mainstream of modern immunology. The
first is that teams of scientists often have
to interact on a regular basis, either within
laboratories, between laboratories, or
among institutions and countries, to solve
the challenges of vaccine biology. There
are just too many unknowns when it
comes to antigens, adjuvants, and protective immune responses (Figure 1).
Nevertheless, on a more hopeful note as
emphasized here, many medical conditions can now be addressed from the
focused perspective of vaccination.
The second difference from what immunologists are accustomed to is that
vaccine science involves humans, not
only mice. I am not referring to large-scale
clinical trials testing whether existing
practices and concepts are effective.

Rather, we need to work out principles
that govern the regulation of the human
immune system in vivo and integrate this
research with other medical sciences
such as microbiology, genetics, and cancer biology. Basic research in humans is
much more demanding in terms of costs,
multiple regulations, and time constraints.
Along with our current successful research enterprise, we now need to expand our research to study directly in patients the distinct pathogens and medical
conditions that threaten us.
The third difference is that vaccine science involves discoveries that differ from
what most scientists are so good at,
which is to dissect disease-relevant
mechanisms. The other less followed research path, which is imperative for vaccine science, is to identify basic principles
that direct immune responses and apply
these to ‘‘develop innovative solutions
that do better than nature.’’ It is important
to dissect immune function in model systems. But it is equally challenging to discover how to direct immunity to create
vaccines that guide the human immune
system. Dendritic cells, as key orchestrators of these responses in vivo, should
help in the quest to bring new vaccines
into medicine.
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